ACAD Acadia Pharmaceuticals Inc. announces disappointing results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
cns适应症，负面结果
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
ACAD Acadia Pharmaceuticals Inc. announces disappointing results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
cns适应症，负面结果